Supernus Pharmaceuticals Joins Neuropsychiatry Summit
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is leading the way in biopharmaceutical innovation geared towards treating diseases of the central nervous system (CNS). With a strong focus on improving patient care, the company is thrilled to announce its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. On this important day, Jack Khattar, Supernus' President and CEO, will join the event virtually, engaging in meaningful discussions about the future of CNS therapies.
Details on the Upcoming Fireside Chat
This virtual fireside chat is set for Thursday, September 26, 2024, at 8:40 a.m. ET. Khattar's presence at the summit highlights Supernus' commitment to addressing neuropsychiatric disorders. Attendees can look forward to gaining valuable insights into the company’s strategies and future plans for developing innovative therapies aimed at CNS conditions.
How to Access the Live Webcast
If you're interested in following the discussions, you'll be able to watch a live webcast. You can easily access it through Supernus Pharmaceuticals' official website, making sure that stakeholders can stay up-to-date on the latest developments in neuropsychiatry and Supernus' contributions to this vital field.
Supernus' Product Portfolio and Commitment to CNS Care
Supernus Pharmaceuticals features a diverse product portfolio targeting key areas within the CNS landscape. Their current offerings include effective treatments for conditions such as epilepsy, migraines, ADHD, and more. Moreover, the company is actively working to address complex challenges like hypomobility related to Parkinson's disease and other CNS disorders, showcasing their relentless drive for medical innovation.
Focus on Research and Development
The company is in the process of developing new therapies that hold significant promise for improving patients' lives. As they expand their offerings, Supernus is committed to delivering safe and effective treatments aligned with patients' ever-changing needs. With robust clinical trials and extensive research, the organization is determined to find and introduce groundbreaking solutions for neurological health.
Core Philosophy and Vision
Supernus Pharmaceuticals operates with a core philosophy centered on enhancing patient outcomes. The leadership team believes that investing in innovative research and focusing on patient care can make a meaningful difference in the healthcare community. Their dedication to improving the quality of life for those battling CNS-related conditions drives their ongoing work and collaboration throughout the industry.
Looking Ahead: The Future of Supernus Pharmaceuticals
The outlook for Supernus is bright as the company continues to explore new avenues in CNS treatment. With various projects underway, stakeholders can expect a range of promising developments that will enhance their already impressive product lineup. As they progress, Supernus remains dedicated to meeting unmet medical needs and ensuring that innovative treatment options are readily available to those in need.
Contact Information
If you have any further questions, please reach out to the Supernus Pharmaceuticals team:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Phone: (301) 838-2591
You can also contact Peter Vozzo
ICR Westwicke
Phone: (443) 213-0505
Email: peter.vozzo@westwicke.com
Frequently Asked Questions
What is Supernus Pharmaceuticals' main focus?
Supernus Pharmaceuticals is committed to developing and commercializing products for the treatment of CNS diseases.
When will the summit take place?
The TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit is scheduled for September 26, 2024.
Who will represent Supernus at the summit?
Jack Khattar, the President and CEO, will represent Supernus Pharmaceuticals in a fireside chat.
How can I watch the live presentation?
The live webcast can be accessed through the Supernus Pharmaceuticals website on the day of the event.
What types of treatments does Supernus Pharmaceuticals offer?
Supernus offers treatments for epilepsy, migraines, ADHD, and several other CNS conditions.